| Course | DNP 955 DPI Project: Part I |
|---|---|
| Topic | Topic 1 |
| Paper type | Practice problem revisited |
| Length | About 1,020 words, 3 pages |
| Format | APA 7 student paper |
| School | Grand Canyon University (GCU) |
| Program | DNP |
| Updated | October 2026 |
Free sample paper for DNP 955 Topic 1
The Gap Shrank While I Was Writing About It: Revisiting a Statin Prescribing Problem for Adults With Diabetes and Narrowing It to Where It Persists
[Author Name]
College of Nursing and Health Care Professions, Grand Canyon University
DNP-955: DPI Project: Part I
Topic 1 Assignment
[Instructor Name]
June 4, 2029
The organization, setting and figures below are a composite written as a model document. No real employer, client, colleague or patient is described.
The Gap Shrank While I Was Writing About It: Revisiting a Statin Prescribing Problem for Adults With Diabetes and Narrowing It to Where It Persists
The Problem as First Written
My practice problem was first written in DNP-820 using data from the four quarters of 2027. In the composite six-clinic primary care network where I practice as one of its family nurse practitioners, 2,340 adults aged 40 to 75 had type 2 diabetes and no atherosclerotic cardiovascular disease, and 58 percent had an active statin on their medication list at the end of the year. National guidelines recommend at least moderate-intensity statin therapy for adults with diabetes in this age range, whatever their estimated risk (Grundy et al., 2019; American Diabetes Association Professional Practice Committee, 2025), so 42 percent of the population, roughly 980 people, were not receiving a therapy with strong evidence of reducing heart attack and stroke. The figure was in line with national data, which showed statin use among adults with diabetes rising to about half by 2011 to 2014, with lower use among women and Black patients (Gu et al., 2018).
Before building an intervention on that figure, I rechecked it with the most recent four quarters, April 2028 through March 2029. The purpose of a revisit is to test the problem, not restate it, and a practice problem written on data more than a year old may no longer describe the practice.
What the Current Data Show
The current figure is 66 percent: 1,622 of 2,458 eligible adults had a statin recorded in the most recent period. The gap has narrowed from 42 to 34 percentage points, a meaningful change of eight points in about a year. It would have been easy, and wrong, to keep using the 2027 figure in the proposal because it made the problem look larger and the project more necessary. The proposal will report the current figure, and it will say that the older one is no longer accurate.
Why It Changed
Two things changed between the periods, and both matter. The first is a separate initiative that addressed part of the same process. In mid-2028, the network's largest Medicare Advantage plan began a pharmacy outreach program for its members with diabetes who were not on statins, because statin use in diabetes is one of the measures the plan's quality ratings depend on. Plan pharmacists called patients and faxed prescribers a request to start a statin. Among the network's Medicare Advantage members aged 65 to 75 with diabetes, statin use rose from 64 to 79 percent over the period; in every other group, it rose by two points or less.
The second is a change in the definition of one measure. In January 2029, the network's quality team changed its statin measure from an active statin on the medication list to a statin ordered or dispensed at any time in the measurement year, using pharmacy claims where the network had them. The new definition counts patients who filled one prescription in the spring and stopped, whom the old definition would have missed if the statin was later removed from their list. When I recalculated the current period with the old definition, the figure was 63 percent rather than 66. So roughly three of the eight points of improvement are a change in how the measure is counted, not a change in care, and the rest came mostly from one payer's program for one age group.
Where the Gap Persists
Breaking the current figure down shows that the improvement is concentrated and the gap is not. Among adults aged 65 to 75, statin use is now 77 percent. Among adults aged 40 to 54, it is 49 percent, and it has barely moved: it was 47 percent in 2027. The younger group is also the one the Medicare Advantage program never reached, because almost none of them are in Medicare. National data point the same way, with statin use increasing with age among adults with diabetes (Gu et al., 2018). Among patients aged 40 to 54 with diabetes in the network, 612 of 1,198 are not on a statin, and they have decades of cardiovascular risk ahead of them.
The chart review of a random 50 of the 612 adds texture that the counts cannot. In 19 charts there was no documented discussion of a statin at all. In 14, a statin had been discussed and the patient had declined or deferred, most often citing worry about side effects or not wanting another daily pill. In 9, a statin had been prescribed once and not refilled. The remaining 8 had a documented reason not to prescribe, such as pregnancy planning or a prior adverse reaction, and should be excluded from the denominator. The mix matters: a project aimed only at prescribers would reach the first group and miss the second and third.
The Problem, Restated
The problem is restated to fit what is now true: among adults aged 40 to 54 with type 2 diabetes and no atherosclerotic cardiovascular disease in the network's six clinics, 49 percent have a statin ordered or dispensed in a 12-month period, measured with the network's current definition, against a guideline expectation that nearly all without a contraindication should be offered one. The population is narrower than before, and the project is smaller. It is also more defensible, because it targets the group where no other initiative is working, and it uses the measure the network now reports, so the project's results will be comparable with the network's own figures.
It is far better to discover this now than in the middle of implementation. Had the project gone ahead with the 2027 problem statement, it would have spent part of its effort on patients aged 65 to 75 who are already being contacted by their health plan, and at evaluation it would have credited itself with improvement caused partly by a measurement change and partly by someone else's program. The revisit cost two days of data work. Finding the same thing after six months of implementation would have cost the project its credibility.
References
American Diabetes Association Professional Practice Committee. (2025). 10. Cardiovascular disease and risk management: Standards of care in diabetes-2025. Diabetes Care, 48(Suppl. 1), S207-S238. https://doi.org/10.2337/dc25-S010
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., Goldberg, R., Heidenreich, P. A., Hlatky, M. A., Jones, D. W., Lloyd-Jones, D., Lopez-Pajares, N., Ndumele, C. E., Orringer, C. E., Peralta, C. A., . . . Yeboah, J. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 139(25), e1082-e1143. https://doi.org/10.1161/CIR.0000000000000625
Gu, A., Kamat, S., & Argulian, E. (2018). Trends and disparities in statin use and low-density lipoprotein cholesterol levels among US patients with diabetes, 1999-2014. Diabetes Research and Clinical Practice, 139, 1-10. https://doi.org/10.1016/j.diabres.2018.02.019
Reading the GCU DNP 955 Topic 1 instructions
Topic 1 in DNP-955 asks students to revisit their practice problem with current data as the DPI Project begins. Strong papers quote the problem exactly as first written, then report what current data show, with numerators, denominators and dates, and explain any change honestly, including improvements the student did not cause. Students should break the current figure down to find where the gap persists, check whether measure definitions changed between periods and restate the problem to fit what is now true. Finding that a problem has narrowed is a useful result at this stage, because it lets the project aim where the gap remains rather than where it used to be, and guidelines such as the ADA standards should confirm the target population.
How the DNP-955 Topic 1 example is put together
The finished example treats the revisit as a test rather than a restatement. The problem was written on figures from four quarters, and the current four quarters show the gap smaller by a meaningful margin, which the paper reports rather than quietly using the older data. It then asks why, finding that a separate initiative addressed part of the same process and that the definition of one measure changed in between. Both are consequential. The problem is restated to fit what is now true, with the population narrowed to the subgroup where the gap persists. The example is explicit that this is better discovered now than in the middle of implementation.
DNP 955 Topic 1 rubric: what Excellent looks like
Faculty reward a problem checked against current data. An Excellent paper quotes the DNP-820 wording and reports 66 percent, 1,622 of 2,458, on a statin. Credit goes to tracing the narrowing to a separate initiative and a measure change, with ADA standards and the ACC/AHA cholesterol guideline by Grundy and colleagues defining eligibility. The rubric values breaking the figure down by age, finding 77 percent at 65 to 75 and 49 percent at 40 to 54, with Gu and colleagues on national use. Top marks go to a problem restated where the gap persists.
DNP 955 Topic 1 help before you submit
Revisits that restate the original problem with no fresh data are the most common submission and defeat the purpose of the topic. A second failure is noticing a changed figure and continuing with the original framing anyway, which will surface during implementation at far greater cost. Marks also go for reporting a change without investigating it, since a concurrent initiative or a definitional shift alters what the project should do. Comparisons drawn over different period lengths are not comparisons. Revised problems presented with no downstream consequences imply the rest of the proposal is unaffected. Statements that widen the population to preserve a gap are working backwards. Audits performed against remembered figures rather than a fresh extract prove nothing about the present.
Get a DNP-955 Topic 1 example written to your instructions
Send the DNP-955 Topic 1 instructions and the rubric your classroom posts, with your practice problem and site data. We write a custom example to those criteria, auditing the original wording against current figures, investigating any change and naming the downstream consequences, in 24 to 48 hours. The first is free.
More DNP 955 papers and DNP samples
- DNP 955 Topic 2: Project Decision Record
- DNP 955 Topic 3: Clinical Question and Population Tightening
- DNP 955 Topic 4: Literature Arranged by Argument
- DNP 955 Topic 5: Framework and Design Defense
- DNP 955 Topic 6: Site Approval DQ Pair
- DNP 955 Topic 7: Measurement and Analysis Plan Draft
- DNP 955 Topic 8: Proposal Assembly and Consistency Pass
- DNP 960A Topic 1: Site Readiness Report
- DNP 840 Topic 1: Clinical Authority Analysis
- DNP 965A Topic 1: Prespecified Analysis Report
- DNP 838A Topic 1: Program Director Role Analysis
DNP 955 Topic 1 questions, answered
What if my problem has gone away?
Then finding out now is the most valuable thing this topic can do for you. A gap that closed because another initiative addressed the same process is a real finding, and continuing with a project aimed at it wastes a year. The usual resolution is narrowing to a subgroup where the gap persists, which is a smaller and more defensible project.
Why quote the original wording exactly?
Because problem statements drift, and the drift is invisible from inside. A statement that began as a specific measure in a specific group frequently softens over a year into something broader that the current data appears to support. Putting the original next to the current figures makes any drift immediately visible, which is the entire point of the audit.
A measure definition changed. Does that matter?
Substantially, and it is easy to miss. If the denominator or the inclusion rule changed between your baseline and now, the two figures are not comparable and any apparent improvement or deterioration may be an artifact. Establishing that the definition held, or reporting that it did not, protects everything the proposal builds on that number.
Where can I find a free DNP 955 Topic 1 sample paper?
Every section of the revisited problem appears here: the problem as first written, what current data show, why it changed, where the gap persists and the problem restated. Send your DNP 955 Topic 1 prompt and a paper follows free.
What if my problem has narrowed in DNP 955 Topic 1?
Find where it persists. The overall gap shrank from 42 to 34 points, but adults aged 40 to 54 remained at 49 percent, so the project moved its aim to them.